Judge Dismisses Ixchel's Antitrust Claims Against Biogen

Law360, Fort Wayne (September 12, 2017, 5:13 PM EDT) -- A California federal judge on Tuesday dismissed Ixchel Pharma LLC’s claims alleging Biogen Inc. made an anti-competitive agreement to undermine Ixchel’s development of a treatment for a rare neuromuscular disease, saying the two companies are not competitors.

Though Ixchel was working to develop a drug containing dimethyl fumerate to treat Friedreich’s ataxia, under an agreement with collaborator Forward Pharma FA ApS only Forward would have been able to bring the drug to market, U.S. District Judge William B. Shubb said in an order.

That means Ixchel...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Ixchel Pharma, LLC. v. Biogen Inc.


Case Number

2:17-cv-00715

Court

California Eastern

Nature of Suit

Anti-Trust

Judge

William B. Shubb

Date Filed

April 4, 2017

Law Firms

Companies

Judge Analytics

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.